{"id":2686,"date":"2020-02-20T17:21:45","date_gmt":"2020-02-20T17:21:45","guid":{"rendered":"https:\/\/filtravate.com\/?page_id=2686"},"modified":"2024-09-18T15:02:51","modified_gmt":"2024-09-18T15:02:51","slug":"news","status":"publish","type":"page","link":"https:\/\/neurexistherapeutics.com\/index.php\/news\/","title":{"rendered":"News"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"2686\" class=\"elementor elementor-2686\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-4722a93 elementor-section-height-min-height elementor-section-stretched elementor-section-boxed elementor-section-height-default elementor-section-items-middle\" data-id=\"4722a93\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;,&quot;stretch_section&quot;:&quot;section-stretched&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-a904486\" data-id=\"a904486\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-9dcd479 elementor-widget elementor-widget-heading\" data-id=\"9dcd479\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">News<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-28747a9 elementor-section-full_width elementor-section-stretched elementor-section-height-default elementor-section-height-default\" data-id=\"28747a9\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;stretch_section&quot;:&quot;section-stretched&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-no\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-9d1ce17\" data-id=\"9d1ce17\" data-element_type=\"column\" data-e-type=\"column\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-efada55 elementor-widget elementor-widget-spacer\" data-id=\"efada55\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-702fb33c elementor-section-stretched elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"702fb33c\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;stretch_section&quot;:&quot;section-stretched&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5707d0bc\" data-id=\"5707d0bc\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-d67714d elementor-widget elementor-widget-heading\" data-id=\"d67714d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><a href=\"https:\/\/www.prweb.com\/releases\/neurexis-therapeutics-secures-3-million-nih-grant-to-advance-neuroprotective-treatment-for-global-cerebral-ischemia-302251251.html\" target=\"_blank\">Neurexis Therapeutics Secures $3 Million NIH Grant to Advance Neuroprotective Treatment for Global Cerebral Ischemia<\/a><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-71c18f7 elementor-widget elementor-widget-text-editor\" data-id=\"71c18f7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>September 18, 2024 &#8211; Neurexis Therapeutics, a leading biopharmaceutical company focused on developing neuroprotective interventions, has been awarded a prestigious\u00a0<span class=\"xn-money\">$3 million<\/span>\u00a0Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). <a href=\"https:\/\/www.prweb.com\/releases\/neurexis-therapeutics-secures-3-million-nih-grant-to-advance-neuroprotective-treatment-for-global-cerebral-ischemia-302251251.html\" target=\"_blank\" rel=\"noopener\">&gt;&gt; Read More<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-49472b7 elementor-widget elementor-widget-heading\" data-id=\"49472b7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><a href=\"https:\/\/spannetwork.org\/neurexis\" target=\"_blank\">Neurexis\u2019 neuroprotective peptide is now online in preparation for SPAN 2.0 testing of candidate interventions<\/a><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-55fa40e elementor-widget elementor-widget-text-editor\" data-id=\"55fa40e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>December 27, 2023 &#8211; Stroke afflicts nearly 800,000 Americans each year and often results in cognitive impairment or death, leading to over $35 billion in annual healthcare costs in the United States. Neurexis Therapeutics is developing a neuroprotective drug, tatCN19o, for the prevention of brain damage following stroke. <a href=\"https:\/\/spannetwork.org\/neurexis\" target=\"_blank\" rel=\"noopener\">&gt;&gt; Read More<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bfa1188 elementor-widget elementor-widget-heading\" data-id=\"bfa1188\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><a href=\"https:\/\/www.prweb.com\/releases\/neurexis-therapeutics-new-discoveries-could-revolutionize-treatment-of-alzheimers-and-other-neurological-conditions-301933061.html\" target=\"_blank\">Neurexis Therapeutics: New Discoveries Could Revolutionize Treatment of Alzheimer's and Other Neurological Conditions<\/a><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-10bf326 elementor-widget elementor-widget-text-editor\" data-id=\"10bf326\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>September 20, 2023 &#8211; Neurexis Therapeutics, a biotechnology company committed to reshaping the landscape of neuroprotection, is excited to highlight recent groundbreaking research that could unlock new avenues for Alzheimer&#8217;s disease and other brain disease therapies.\u00a0<a href=\"https:\/\/www.prweb.com\/releases\/neurexis-therapeutics-new-discoveries-could-revolutionize-treatment-of-alzheimers-and-other-neurological-conditions-301933061.html\" target=\"_blank\" rel=\"noopener\">&gt;&gt; Read More<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-eddf6b1 elementor-widget elementor-widget-heading\" data-id=\"eddf6b1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><a href=\"https:\/\/www.asbmb.org\/asbmb-today\/science\/080423\/from-the-journals-jbc\" target=\"_blank\">New Stroke Drug Doesn\u2019t Impair Memory\n<\/a><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0dc7b0e elementor-widget elementor-widget-text-editor\" data-id=\"0dc7b0e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>August 4, 2023 &#8211; Acute CaMKII inhibition using the neuroprotective peptide tatCN19o did not affect pre-formed memories and only mildly and transiently interfered with learning. <a href=\"https:\/\/www.asbmb.org\/asbmb-today\/science\/080423\/from-the-journals-jbc\" target=\"_blank\" rel=\"noopener\">&gt;&gt; Read More<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5b727c7 elementor-widget elementor-widget-heading\" data-id=\"5b727c7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><a href=\"https:\/\/www.prweb.com\/releases\/direct_to_phase_ii_sbir_grant_from_nih_awarded_to_neurexis_therapeutics_to_evaluate_neuroprotective_therapeutic_in_stroke_preclinical_assessment_network_span\/prweb19286851.htm\" target=\"_blank\">Direct-to-Phase II SBIR Grant from NIH Awarded to Neurexis Therapeutics to Evaluate Neuroprotective Therapeutic in Stroke Preclinical Assessment Network (SPAN)<\/a><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8948617 elementor-widget elementor-widget-text-editor\" data-id=\"8948617\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>April 19, 2023 &#8211; Neurexis Therapeutics, Incorporated, announces it has been awarded $900,000 in funding from a Direct-to-Phase II Small Business Innovation Research (SBIR) grant through the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health&#8230; <a href=\"https:\/\/www.prweb.com\/releases\/direct_to_phase_ii_sbir_grant_from_nih_awarded_to_neurexis_therapeutics_to_evaluate_neuroprotective_therapeutic_in_stroke_preclinical_assessment_network_span\/prweb19286851.htm\" target=\"_blank\" rel=\"noopener\">&gt;&gt; Read More<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c7b1bc5 elementor-widget elementor-widget-heading\" data-id=\"c7b1bc5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><a href=\"https:\/\/blog.victech.com\/from-the-corner-office-neurexis-therapeutics\" target=\"_blank\">From the Corner Office: Neurexis Therapeutics<\/a><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c228c27 elementor-widget elementor-widget-text-editor\" data-id=\"c228c27\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>March 7, 2022 &#8211; Let me start by saying that the last two years have been a case study on focusing on priorities and filtering out noise. I\u2019m fortunate to work in an area where it\u2019s easy to see the long-term value of what we do\u2014advancing new technologies&#8230; <a href=\"https:\/\/blog.victech.com\/from-the-corner-office-neurexis-therapeutics\" target=\"_blank\" rel=\"noopener\">&gt;&gt; Read More<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-828e635 elementor-widget elementor-widget-heading\" data-id=\"828e635\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><a href=\"https:\/\/blog.victech.com\/neurexis-therapeutics-awarded-nih-phase-i-sbir-grant\" target=\"_blank\">Neurexis Therapeutics Awarded NIH Phase I SBIR Grant to Accelerate IND-Enabling Studies of Neuroprotective Therapeutic<\/a><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2552329 elementor-widget elementor-widget-text-editor\" data-id=\"2552329\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>October 14, 2021 &#8211; A promising approach for preventing cognitive and behavioral impairment following ischemic events such as cardiac arrest and stroke. Aurora, CO &#8211; Neurexis Therapeutics, Incorporated, announces it has been awarded <a href=\"https:\/\/blog.victech.com\/neurexis-therapeutics-awarded-nih-phase-i-sbir-grant\" target=\"_blank\" rel=\"noopener\">&gt;&gt; Read More<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6f50d60 elementor-widget elementor-widget-heading\" data-id=\"6f50d60\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><a href=\"https:\/\/blog.victech.com\/neurexis-therapeutics-solves-an-unmet-healthcare-need\" target=\"_blank\">Neurexis Therapeutics Works to Solve an Unmet Healthcare Need<\/a><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-101be6e elementor-widget elementor-widget-text-editor\" data-id=\"101be6e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>January 4, 2021 &#8211; CBSA President &amp; CEO, Jennifer Jones Paton, asked Michael Artinger, PhD, Neurexis\u2019 Chief Executive Officer, CBSA\u2019s Key Questions for Life Sciences Innovators. Neurexis Therapeutics relies on innovation to address a substantial unmet medical need: damage to the brain resulting from loss of blood flow <a href=\"https:\/\/blog.victech.com\/neurexis-therapeutics-solves-an-unmet-healthcare-need\" target=\"_blank\" rel=\"noopener\">&gt;&gt; Read More<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-fb08987 elementor-widget elementor-widget-heading\" data-id=\"fb08987\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><a href=\"https:\/\/blog.victech.com\/neurexis-therapeutics-awarded-accelerator-grant\" target=\"_blank\">Neurexis Therapeutics Awarded Colorado Advanced Industries Accelerator Grant<\/a><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0efedfd elementor-widget elementor-widget-text-editor\" data-id=\"0efedfd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>June 18, 2020 &#8211; AURORA, CO &#8211; Neurexis Therapeutics, Inc. announced today that it has been approved for funding as part of the Colorado Office of Economic Development and International Trade\u2019s (OEDIT) Advanced Industries Accelerator Program. The $250,000 Early Stage Capital and Retention Grant will be used to accelerate development of the company\u2019s innovative therapeutic peptide <a href=\"https:\/\/blog.victech.com\/neurexis-therapeutics-awarded-accelerator-grant\" target=\"_blank\" rel=\"noopener\">&gt;&gt; Read More<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ca3cd38 elementor-widget elementor-widget-heading\" data-id=\"ca3cd38\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><a href=\"https:\/\/blog.victech.com\/vic-forms-new-portfolio-company-neurexis-therapeutics\" target=\"_blank\">VIC Technology Venture Development Forms New Portfolio Company: Neurexis Therapeutics<\/a><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-401533c elementor-widget elementor-widget-text-editor\" data-id=\"401533c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>April 8, 2020 &#8211; AURORA, CO &#8211; VIC Technology Venture Development, LLC (VIC) announced today the formation of Neurexis Therapeutics, Inc. to develop a new medication for the prevention of brain damage following ischemic events such as stroke. Licensed from the University of Colorado Anschutz Medical Campus <a href=\"https:\/\/blog.victech.com\/vic-forms-new-portfolio-company-neurexis-therapeutics\" target=\"_blank\" rel=\"noopener\">&gt;&gt; Read More<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-8c49990 elementor-reverse-mobile elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"8c49990\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>News Neurexis Therapeutics Secures $3 Million NIH Grant to Advance Neuroprotective Treatment for Global Cerebral Ischemia September 18, 2024 &#8211; Neurexis Therapeutics, a leading biopharmaceutical company focused on developing neuroprotective interventions, has been awarded a prestigious\u00a0$3 million\u00a0Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). &gt;&gt; Read More Neurexis\u2019 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"class_list":["post-2686","page","type-page","status-publish","hentry"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.1.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"News Neurexis Therapeutics Secures $3 Million NIH Grant to Advance Neuroprotective Treatment for Global Cerebral Ischemia September 18, 2024 \u2013 Neurexis Therapeutics, a leading biopharmaceutical company focused on developing neuroprotective interventions, has been awarded a prestigious $3 million Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). &gt;&gt; Read More Neurexis\u2019\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/neurexistherapeutics.com\/index.php\/news\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.1.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"neurexistherapeutics.com - Neuroprotective Innovation Improving Global Human Health\" \/>\n\t\t<meta property=\"og:type\" content=\"website\" \/>\n\t\t<meta property=\"og:title\" content=\"News - neurexistherapeutics.com\" \/>\n\t\t<meta property=\"og:description\" content=\"News Neurexis Therapeutics Secures $3 Million NIH Grant to Advance Neuroprotective Treatment for Global Cerebral Ischemia September 18, 2024 \u2013 Neurexis Therapeutics, a leading biopharmaceutical company focused on developing neuroprotective interventions, has been awarded a prestigious $3 million Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). &gt;&gt; Read More Neurexis\u2019\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/neurexistherapeutics.com\/index.php\/news\/\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"News - neurexistherapeutics.com\" \/>\n\t\t<meta name=\"twitter:description\" content=\"News Neurexis Therapeutics Secures $3 Million NIH Grant to Advance Neuroprotective Treatment for Global Cerebral Ischemia September 18, 2024 \u2013 Neurexis Therapeutics, a leading biopharmaceutical company focused on developing neuroprotective interventions, has been awarded a prestigious $3 million Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). &gt;&gt; Read More Neurexis\u2019\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/neurexistherapeutics.com\\\/index.php\\\/news\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/neurexistherapeutics.com#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/neurexistherapeutics.com\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/neurexistherapeutics.com\\\/index.php\\\/news\\\/#listItem\",\"name\":\"News\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/neurexistherapeutics.com\\\/index.php\\\/news\\\/#listItem\",\"position\":2,\"name\":\"News\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/neurexistherapeutics.com#listItem\",\"name\":\"Home\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/neurexistherapeutics.com\\\/#organization\",\"name\":\"neurexistherapeutics.com\",\"description\":\"Neuroprotective Innovation Improving Global Human Health\",\"url\":\"https:\\\/\\\/neurexistherapeutics.com\\\/\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/neurexistherapeutics.com\\\/index.php\\\/news\\\/#webpage\",\"url\":\"https:\\\/\\\/neurexistherapeutics.com\\\/index.php\\\/news\\\/\",\"name\":\"News - neurexistherapeutics.com\",\"description\":\"News Neurexis Therapeutics Secures $3 Million NIH Grant to Advance Neuroprotective Treatment for Global Cerebral Ischemia September 18, 2024 \\u2013 Neurexis Therapeutics, a leading biopharmaceutical company focused on developing neuroprotective interventions, has been awarded a prestigious $3 million Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). >> Read More Neurexis\\u2019\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neurexistherapeutics.com\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/neurexistherapeutics.com\\\/index.php\\\/news\\\/#breadcrumblist\"},\"datePublished\":\"2020-02-20T17:21:45+00:00\",\"dateModified\":\"2024-09-18T15:02:51+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/neurexistherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/neurexistherapeutics.com\\\/\",\"name\":\"neurexistherapeutics.com\",\"description\":\"Neuroprotective Innovation Improving Global Human Health\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/neurexistherapeutics.com\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"News - neurexistherapeutics.com","description":"News Neurexis Therapeutics Secures $3 Million NIH Grant to Advance Neuroprotective Treatment for Global Cerebral Ischemia September 18, 2024 \u2013 Neurexis Therapeutics, a leading biopharmaceutical company focused on developing neuroprotective interventions, has been awarded a prestigious $3 million Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). >> Read More Neurexis\u2019","canonical_url":"https:\/\/neurexistherapeutics.com\/index.php\/news\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/neurexistherapeutics.com\/index.php\/news\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/neurexistherapeutics.com#listItem","position":1,"name":"Home","item":"https:\/\/neurexistherapeutics.com","nextItem":{"@type":"ListItem","@id":"https:\/\/neurexistherapeutics.com\/index.php\/news\/#listItem","name":"News"}},{"@type":"ListItem","@id":"https:\/\/neurexistherapeutics.com\/index.php\/news\/#listItem","position":2,"name":"News","previousItem":{"@type":"ListItem","@id":"https:\/\/neurexistherapeutics.com#listItem","name":"Home"}}]},{"@type":"Organization","@id":"https:\/\/neurexistherapeutics.com\/#organization","name":"neurexistherapeutics.com","description":"Neuroprotective Innovation Improving Global Human Health","url":"https:\/\/neurexistherapeutics.com\/"},{"@type":"WebPage","@id":"https:\/\/neurexistherapeutics.com\/index.php\/news\/#webpage","url":"https:\/\/neurexistherapeutics.com\/index.php\/news\/","name":"News - neurexistherapeutics.com","description":"News Neurexis Therapeutics Secures $3 Million NIH Grant to Advance Neuroprotective Treatment for Global Cerebral Ischemia September 18, 2024 \u2013 Neurexis Therapeutics, a leading biopharmaceutical company focused on developing neuroprotective interventions, has been awarded a prestigious $3 million Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). >> Read More Neurexis\u2019","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/neurexistherapeutics.com\/#website"},"breadcrumb":{"@id":"https:\/\/neurexistherapeutics.com\/index.php\/news\/#breadcrumblist"},"datePublished":"2020-02-20T17:21:45+00:00","dateModified":"2024-09-18T15:02:51+00:00"},{"@type":"WebSite","@id":"https:\/\/neurexistherapeutics.com\/#website","url":"https:\/\/neurexistherapeutics.com\/","name":"neurexistherapeutics.com","description":"Neuroprotective Innovation Improving Global Human Health","inLanguage":"en-US","publisher":{"@id":"https:\/\/neurexistherapeutics.com\/#organization"}}]},"og:locale":"en_US","og:site_name":"neurexistherapeutics.com - Neuroprotective Innovation Improving Global Human Health","og:type":"website","og:title":"News - neurexistherapeutics.com","og:description":"News Neurexis Therapeutics Secures $3 Million NIH Grant to Advance Neuroprotective Treatment for Global Cerebral Ischemia September 18, 2024 \u2013 Neurexis Therapeutics, a leading biopharmaceutical company focused on developing neuroprotective interventions, has been awarded a prestigious $3 million Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). &gt;&gt; Read More Neurexis\u2019","og:url":"https:\/\/neurexistherapeutics.com\/index.php\/news\/","twitter:card":"summary_large_image","twitter:title":"News - neurexistherapeutics.com","twitter:description":"News Neurexis Therapeutics Secures $3 Million NIH Grant to Advance Neuroprotective Treatment for Global Cerebral Ischemia September 18, 2024 \u2013 Neurexis Therapeutics, a leading biopharmaceutical company focused on developing neuroprotective interventions, has been awarded a prestigious $3 million Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). &gt;&gt; Read More Neurexis\u2019"},"aioseo_meta_data":{"post_id":"2686","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"website","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2024-06-10 21:14:02","updated":"2025-06-04 05:51:18","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/neurexistherapeutics.com\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tNews\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/neurexistherapeutics.com"},{"label":"News","link":"https:\/\/neurexistherapeutics.com\/index.php\/news\/"}],"_links":{"self":[{"href":"https:\/\/neurexistherapeutics.com\/index.php\/wp-json\/wp\/v2\/pages\/2686","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neurexistherapeutics.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/neurexistherapeutics.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/neurexistherapeutics.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/neurexistherapeutics.com\/index.php\/wp-json\/wp\/v2\/comments?post=2686"}],"version-history":[{"count":0,"href":"https:\/\/neurexistherapeutics.com\/index.php\/wp-json\/wp\/v2\/pages\/2686\/revisions"}],"wp:attachment":[{"href":"https:\/\/neurexistherapeutics.com\/index.php\/wp-json\/wp\/v2\/media?parent=2686"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}